Search results
Showing 61 to 75 of 282 results for covid
Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards
FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)
NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing .
of specific antifungal treatments for treating suspected or confirmed COVID-19-associated pulmonary aspergillosis (CAPA),...
psychiatric aspects) for post-COVID-19 syndrome in a UK population. What tools are validated for screening for...
This guideline covers interventions to prevent sexually transmitted infections (STIs) in people aged 16 and over. It aims to reduce the transmission of all STIs, including HIV, and includes ways to help increase the uptake of STI testing and vaccines for human papillomavirus (HPV) and hepatitis A and B.
Behaviour change: digital and mobile health interventions (NG183)
This guideline covers interventions that use a digital or mobile platform to help people eat more healthily, become more active, stop smoking, reduce their alcohol intake or practise safer sex. The interventions include those delivered by text message, apps, wearable devices or the internet. The guideline only includes those that are delivered by the technology itself and not by healthcare professionals using technology to deliver interventions.
standard care or conventional oxygen therapy for people in hospital with COVID-19 and respiratory failure when it is agreed...
Social, emotional and mental wellbeing in primary and secondary education (NG223)
This guideline covers ways to support social, emotional and mental wellbeing in children and young people in primary and secondary education (key stages 1 to 5), and people 25 years and under with special educational needs or disability in further education colleges. It aims to promote good social, emotional and psychological health to protect children and young people against behavioural and health problems.
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]
In development Reference number: GID-TA10606 Expected publication date: TBC
Appraisal is the process of determining which records have continuing business or historical value from those which have no further value and should be disposed of appropriately.
NG188/2 Question What is the prevalence and incidence of post-COVID-19 syndrome in patients who have received single,...
Cemiplimab for treating advanced cutaneous squamous cell carcinoma (TA802)
Evidence-based recommendations on cemiplimab (Libtayo) for metastatic or locally advanced cutaneous squamous cell carcinoma in adults.
and safety of the combination of casirivimab and imdevimab for treating COVID-19 in people with particular clinical...
Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.
Read the biographies for all members of the NICE antimicrobial evaluation committee.